Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sir_Holleron Aug 02, 2015 10:39pm
85 Views
Post# 23984179

RE:RE:RE:RE:RE:Tuesdays price action

RE:RE:RE:RE:RE:Tuesdays price action"the Herceptin news got us red that day, why would anyone be expecting a pop from lsd?"

The ability to predict human outcomes with a mouse model when it comes to brain cancer isn't as strong as the ability to predict human outcomes with a mouse model and Hunter's Syndrome. Rob said that Lysosomal Storage Disease was the perfect model to test Transcend in that it involves just a single mutation and if you can deliver the enzyme where it needs to go you have soved the problem - there is a perfect read-out. Brain cancer is more complex and may only extend life by months. There is also a better validation concerning how mouse testing translates to human testing with Lysosomal Storage Disease I believe.

BTI may have much more information than we were given in the last news release concerning various doseing regimes, and how much of the problem remained in the Scarpa study. Those close to BTI may have an advantage.
Bullboard Posts